Doctors test gene therapy to protect brain cells in Parkinson's patients
NCT ID NCT04167540
Summary
This early-stage study is testing the safety of a new gene therapy for Parkinson's disease. Researchers are delivering a gene called GDNF directly into a specific brain region in 11 participants to see if it can protect the cells that produce dopamine. The main goal is to check for side effects, but they will also monitor changes in movement symptoms and brain scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Ohio State University Medical Center
Columbus, Ohio, 43210, United States
-
University of California Irvine
Irvine, California, 92697, United States
-
University of California San Francisco
San Francisco, California, 94103, United States
Conditions
Explore the condition pages connected to this study.